Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 20/20 | 0.80 |
| ▸ | PRKAB2 | O43741 | 16/20 | 0.80 |
| ▸ | PRKAG1 | P54619 | 16/20 | 0.80 |
| ▸ | PRKAA1 | Q13131 | 16/20 | 0.80 |
| ▸ | PRKAG3 | Q9UGI9 | 16/20 | 0.80 |
| ▸ | PRKAG2 | Q9UGJ0 | 16/20 | 0.80 |
| ▸ | PRKAB1 | Q9Y478 | 16/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518324 | 0.89 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518146 | 0.89 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518494 | 0.88 | PRKAA2 (0.67) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL517982 | 0.88 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518142 | 0.88 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL519198 | 0.87 | PRKAA2 (0.85) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518724 | 0.86 | PRKAA2 (0.92) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518552 | 0.85 | PRKAA2 (0.79) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518208 | 0.85 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL519345 | 0.85 | PRKAA2 (0.91) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | claimed |
| WO-2015048547-A2 | METHODS FOR USING AND BIOMARKERS FOR AMPK-ACTIVATING COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | claimed |
| EP-2598483-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | claimed |
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | claimed |
| WO-2012016217-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | claimed |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-9663496-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20130267701-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | MIDCAP FINANCIAL TRUST | 2013-10-10 | — | — | US | disclosed |
| US-20130267701-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | MIDCAP FINANCIAL TRUST | 2013-10-10 | — | — | US | disclosed |
| US-20130203987-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203987-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2598483-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012016217-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012016217-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028954-A1 | Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same | AK2, PC, PRKAG2 | PRKAA2 6/4885PRKAB2 5/4885PRKAG1 4/4885 |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PRKAA2 7/4885PRKAB2 5/4885PRKAG1 1/4885 |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | PRKAA2 7/4885PRKAB2 5/4885PRKAG1 1/4885 |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | PRKAA2 7/4885PRKAB2 5/4885PRKAG1 1/4885 |
| US-20130203987-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PRKAA2 7/4885PRKAB2 5/4885PRKAG1 1/4885 |
| US-20130267701-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PRKAA2 7/4885PRKAB2 5/4885PRKAG1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.